Background: Caregivers play a major role in providing care for patients with Alzheimer's disease (AD) and are themselves at higher risk of health comorbidities. Aim: To address the impact of neuropsychiatric symptoms of patients in different stages of AD on their caregivers' burden. Design: This prospective study enrolled 260 AD patients with clinical dementia rating (CDR) of 0.5, 1 and 2 at a tertiary medical center.
Introduction
Population aging is a global phenomenon, and more than half (55%) of the world's older population lives in Asia, as of 2012. 1 In
Taiwan, 12% of the population was over 65 years of age at the end of 2014. 2 In addition, cases of dementia are increasing among the aging population worldwide, with a current global estimate of about 35.6 million cases. This number is expected to almost double by 2030 and to more than triple by 2050. 3 The prevalence of dementia is 5.7% in Taiwan and is expected to double by 2030. 4 Alzheimer's disease (AD) is the most common form of dementia and is responsible for progressive impairment of cognitive and functional performance, and for behavioral disorders. 5, 6 As the AD population increases remarkably, early identification of dementia and care from primary physicians are important, as these measures allow patients with dementia and their family care networks to engage with support services and plan for the future. Patients with AD often present with behavioral and psychological symptoms of dementia (BPSD). Hence, understanding its presentations and severity grading are important for designing treatment strategies and relieving caregivers burden. People with AD require high levels of care, 7 most of which is provided by informal or family caregivers. This support typically comes at various costs to caregivers, including distress, reduced quality of life, higher risk of anxiety, depressive and sleep disorders and higher risk of cardiovascular morbidity and mortality. [8] [9] [10] [11] Previous studies have validated the neuropsychiatric inventory (NPI) score reliability 12 and its relationships with antipsychotic treatment 13 and Parkinson's disease dementia. 14 The current hospital-based study aimed to provide data on neuropsychiatric symptoms in patients with AD and to evaluate whether dementia severity affects the NPI domains and caregiver burden. Research involving the pathology of BPSD in AD and therapeutic outcomes have been limited. 7, 15, 16 Recent studies showed that BPSD in patients with AD were positively correlated with cerebrospinal fluid (CSF) levels of both total tau and phosphorylated-tau, 7 and reversely correlated with CSF cytokine IL-10. 15 Clinical studies support that anti-Alzheimer's drugs (e.g. glutamine) can be safe and used as a first line treatment for BPSD, unless in cases of prominent irritation and agitation, for which antipsychotic drugs (e.g. risperidone) are more efficient. 16 To our knowledge, only limited information is available regarding longitudinal functional outcomes of Asian patients with AD undergoing treatment with anti-Alzheimer's drugs. Given the effects of neuropsychiatric symptoms on caregivers' distress, it is important to determine which neuropsychiatric symptoms in patients with AD warrant preventive intervention.
Materials and methods

Study design
This prospective study was conducted at Chang Gung Memorial Hospital-Kaohsiung, a tertiary medical center and main referral hospital serving a population of 3 million in southern Taiwan.
Inclusion and exclusion criteria
The study participants were treated at the Cognition and Aging Center, Department of General Neurology, Chang Gung Memorial Hospital-Kaohsiung. The clinical diagnosis of AD was reached by a panel composed of neurologists, neuropsychologists, neuroradiologists and experts in nuclear medicine, [15] [16] [17] [18] [19] 
Clinical data collection
The clinical features of patients recorded for this study were age at disease onset (or age at the time of the first reported symptom attributable to the disease) and years of education.
Neuropsychiatric testing and outcome
The mini-mental state examination (MMSE) was used to assess general intellectual function. 22 The ability to perform digit forward span test was also performed. Cognitive outcomes were assessed using the clinical dementia rating (CDR) scale since it scores the functional capacity of participants independent of physical disability. 23 All subjects were assigned a CDR rating score as follows: 0 indicated no dementia, and scores of 0.5, 1 and 2 indicated MCI, mild and moderate dementia, respectively. The CDR scale sum of boxes (CDR-SB) was obtained by adding the domain box scores (memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care), ranging from 0 to 18. The CDR-SB score is used to investigate and stage dementia severity accurately. 24 The cognitive abilities screening instrument (CASI C-2.0) consists of 20 items divided into 9 domains including attention, concentration, short-and long-term memory, orientation, language abilities, visual construction, abstraction, judgment and category fluency. 25, 26 The sum of the scores ranges from 0 to 100, with higher scores indicating better cognitive ability. We used the 12-item version of the NPI, which divides mental/behavioral phenomena into 12 domains on the basis of observations within the past month. 27 All domains were rated on symptom frequency from 1 (occasionally) to 4 (very frequently), on symptom severity from 1 (mild) to 3 (severe) and on caregiver burden from 0 (none) to 5 (extreme). The means of the variables of the subscale (frequency Â severity) and caregiver burden in each NPI domain were also analysed. Our standard therapeutic regimen was to prescribe antiAlzheimer's drugs in patients with clinical diagnosis of AD and approved by Taiwan national health insurance. The commencement of anti-Alzheimer's drugs in patients with AD could be different for each patient depending on their doctor preference.
Statistical analysis
Three separate statistical analyses were performed. First, the effects of individual categorical variables, including sex and underlying diseases among different groups of dementia severity (i.e. groups based on CDR rating scores equal to 0.5, 1 and 2), were analysed by Chi-square or Fisher's test. Continuous variables including age, frequency, severity, NPI sub-scores, caregiver burden scores, mean MMSE score and CASI sub-scores among the different groups of dementia severity were analysed using Kruskal-Wallis test or one-way ANOVA test. Correlation analysis was used to explore the relationships between the NPI sub-scores and the Caregiver Burden Inventory, between CDR-SB and MMSE scores, and between the sum of Caregiver Burden Inventory (NPI-burden) and the scores of MMSE, CASI and variables such as age and years of education. Multiple linear regression analyses were performed to evaluate the influence of independent variables on mean NPI-burden. The longitudinal therapeutic outcomes resulting from treatment with antiAlzheimer's drugs were classified into good (follow-up period-> or ¼ 29 months) and poor (follow-up period < 29 months) outcome groups according to the median value for the patient follow-up periods (median ¼ 29 months). All statistical analyses were conducted using SAS software version 9.1 (SAS Statistical Institute, Cary, North Carolina, 2002).
Results
Baseline characteristics of study patients
The 260 patients with AD included 99 male participants (age range, 58-95 years; mean age, 77.3 years) and 161 female participants (age range, 54-92 years; mean age, 77.3 years). Regarding the severity level of dementia, 117 patients had MCI, 103 had mild dementia and the remaining 40 had moderate dementia ( Table 1 ). The mean values and standard deviations of the three groups (MCI, mild dementia and moderate dementia, respectively) were as follows: age: 75.5 6 8.1, 77.4 6 8.8 and 81.9 6 8.3 (P < 0.0001); number of years of education: 7.6 6 4.9, 6.0 6 5.0 and 4.7 6 3.5 (P ¼ 0.002); total CASI scores: 75.5 6 19.4, 47.3 6 17.0 and 19.8 6 16.4 (P < 0.0001); MMSE scores: 22.4 6 4.2, 13.9 6 4.6 and 6.7 6 4.5(P < 0.001). The median sums of the caregiver burden (NPI-burden) of the three groups were 0 (0-3.0), 3.0 (0-10.0) and 4.5 (0-10.8), respectively (P < 0.0001). The median sums of the 12 NPI domain sub-scores (frequency Â severity) (NPI-sum) of the three groups were 2 (0-12), 12 (4-24) and 18 (6-32), respectively (P < 0.0001) ( Table 1) .
Correlation between NPI sub-scores and caregiver burden inventory (NPI-sum)
Correlation analysis was used to test the influence of each of the 12 NPI sub-scores on the sum of caregiver burden in 12 NPI domains (NPI-burden), on the CDR-SB and on the sum of 9 CASI domains of the CASI (average) ( Table 2 ). The statistical results showed that all 12 NPI sub-scores were positively correlated with NPI-burden. In addition, except for four domains of NPI sub-scores (depression, anxiety, euphoria and sleep), the remaining eight domains showed a positive correlation with the CDR-SB score (average), but were negatively correlated with MMSE score (average).
Effects of MMSE, CASI, age and years of education on NPI-burden
Correlation analysis was used to test the influences of different variables on NPI-burden. The variables, their respective correlation coefficients and P-values were as follows: age (r ¼ À0.023, P ¼ 0.707), years of education (r ¼ À0.140, P¼ 0.024), CASI (r ¼ À0.259, P < 0.001), MMSE (r ¼ À0.262, P < 0.001) and NPI-sum (r ¼ 0.822, P < 0.001). The results are listed in Table 3 .
NPI-burden is independently associated with NPI-sum
The factors that were significantly correlated with NPI-burden were chosen for inclusion in multiple linear regression analysis ( Table 4 ). The results showed that only NPI-sum was independently associated with mean NPI-burden. The multiple linear regression formula was calculated as follows: NPI-burden ¼ À (0.344 þ 0.366) Â (NPI-sum).
Therapeutic outcomes of anti-Alzheimer's drugs
The mean follow-up interval was 25.0 6 12.2 months. Two of the patients died during the follow-up. Twenty-nine of the patients required psychiatric assessments during this period because of Regarding the longitudinal therapeutic outcomes of antiAlzheimer's drugs determined by the median value of the follow-up period (median ¼ 29 months), the statistical results for the two groups (good and poor therapeutic outcomes, respectively), were as follows: mean age: 77.0 6 12.3 years and 77.5 6 9.4 (P ¼ 0.640); mean number of years of education: 5.9 6 4.9 years and 6.9 6 5.3 years (P ¼ 0.104); mean CASI score: 60.7 6 22.7 and 50.4 6 27.7 (P ¼ 0.001); mean MMSE score: 17.8 6 6.4 and 15.3 6 7.8 (P ¼ 0.005); median NPI-sum: 8 (0, 20) and 9 (1, 18) (P ¼ 0.873); median NPI-burden: 1.5 (0, 6) and 1.5 (0, 6) (P ¼ 0.630).
Discussion
The present study examined the association between neuropsychiatric symptoms in AD and increased caregiver burden in 260 patients with different severities of dementia using the CDR scale, and obtained three major findings. First, the severity of neuropsychiatric symptoms and caregiver stress were both in proportion to the severity of dementia. Second, only specific domains of the NPI, including those regarding delusions, hallucinations, agitation, apathy, aberrant motor behaviors and appetite/eating, were related in a similar and logically progressive way to the mean scores of the CDR-SB and MMSE. Finally, the caregiver burden was correlated with years of education, cognitive ability and general intellectual functioning. Therefore, this report provides a predictable image of the direction for management of patients with AD.
Differences in the relative frequency and severity of neuropsychiatric symptoms in patients with dementia vary according to case determination, racial differences, inclusion criteria, disease severity and duration, length of follow-up and complications related to dementia and/or medication. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Caregivers of patients with dementia are known to have a higher risk of reduced quality of life and cardiovascular morbidity and mortality. 40, 41 One study showed that neuropsychiatric symptoms were very common in patients with vascular cognitive impairment with or without dementia, and that the frequency of any symptom in the NPI was up to 90% among all participants. 30 Among these symptoms, sleep disturbance, depression and apathy were the most common. 30 Another study showed that the frequency and severity of apathy, hallucinations, agitation, aberrant motor behaviors and caregiver burden score were low. 29 In this study, the total NPI scores were not related to the prediction of treatment duration. In contrast, cognitive decline was more obvious in the poor treatment group. Based on this finding, neuropsychiatric presentation in AD might significantly affect the caregiver burden, and the cognitive function is closely related to the treatment outcomes in patients with AD. In terms of neuropsychiatric symptoms, several studies have focused on the prevalence of delusions and caregiver stress. [33] [34] [35] [36] [37] [38] [39] In several of those studies, the prevalence of delusions was reported to range from 10 to 73% in the moderate-to-late stages of AD. [33] [34] [35] One study indicated that delusion symptoms in patients with AD were more frequent among ethnic Chinese patients than among Caucasian patients. 36 Another study found that delusional ideation was significantly associated with hallucinations, aggressiveness and affective disturbances in elderly ethnic Chinese patients with AD. 37 Other studies from Taiwan have found that delusions were the most distressing symptoms for caregivers, and the NPI score was a reliable tool to assess behavioral disturbances and caregiver distress relative to AD cases. 38, 39 In contrast to previous cross-sectional studies assessing the impact of neuropsychiatric symptoms in patients with AD on caregiver burden, [12] [13] [14] our study demonstrated that patients with higher mean CASI and MMSE scores had better therapeutic outcomes from treatment with anti-Alzheimer's drugs than patients with lower scores. This finding might imply that diagnosis of the disease during early phases of dementia coupled with early intervention to reduce the subsequent impacts of dementia could lead to better therapeutic outcomes resulting from treatment with anti-Alzheimer's drugs. Our study has several limitations. First, it might be subject to the bias of unmeasured factors. The etiologies of neuropsychiatric symptoms among patients with AD might be multifactorial, and can include underlying AD, medical comorbidities and drugrelated complications. For example, depression and anxiety almost inevitably emerge with disease progression and might dominate the clinical picture of advanced AD, in addition to contributing to severe disability and impaired quality of life. Second, the dose and choice of different drugs on different NPI in the patients who had AD was different for each patient, based on the preference of the primary physician. Therefore, the effects of types of drugs and dosages on different NPI have not been analysed. Third, AD is a slowly progressing neurodegenerative disorder. Neuropsychiatric symptoms and cognitive decline at baseline after enrollment might thus change after the use of medications for cognitive decline or psychiatric symptoms. Further long-term longitudinal studies and investigations of individual differences and patient profiles, besides the investigation of predictors for varying neuropsychiatric symptom profiles are needed.
In conclusion, our study revealed that the severity of neuropsychiatric symptoms in patients with AD was positively associated with caregiver stress. Patients with better cognitive functions and under anti-Alzheimer's drug treatments had better longitudinal therapeutic outcomes. Our study also demonstrated that neuropsychiatric symptoms, including delusions, hallucinations, agitation, apathy, aberrant motor behaviors and appetite/eating symptoms, were more severe when the degree of AD was progressive; the effects of AD on caregiver stress were also more severe. To reduce the impact of neuropsychiatric symptoms, it is crucial to detect dementia in its early phases and to provide early intervention with anti-Alzheimer's drugs, which might help decrease the caregiver burden and improve their quality of life.
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